Author: sugaradmin

Introduction and Objective: Fast-acting insulin analogs (FIA) have earlier and higher peak and shorter duration of action as compared with short-acting human insulin (SHI). Therefore, their pharmacokinetic profile would rather reflect glycemic profile after high-carbohydrate meal (HCM), whereas delayed and longer action of SHI would rather reflect glycemia after low-carbohydrate meal (LCM).Methods: In a cross-over, […]

Introduction and Objective: Diabetic retinopathy (DR) is associated with hyperglycemia and inflammatory biomarkers such as Vascular Endothelial Growth Factor. Another molecule, Endocrine Gland-derived Vascular Endothelial Growth Factor (EG-VEGF) is present in human sera and is hypothesized to play a role in angiogenesis. We aim to determine whether DR severity is correlated to circulating levels of […]

Introduction and Objective: This trial assessed the PD, PK, and safety of SHR-3167 vs IGlar U100 in healthy subjects.Methods: This was an open-label, two-period, single-sequence trial. Sixteen healthy males were enrolled into two cohorts. Both cohorts received a single injection of IGlar U100 (0.4 U/kg), following a 7-day washout, and then received a single injection […]

Introduction and Objective: Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) affects ~60% of those with T2DM yet is under-recognized, even in specialty endocrinology practices. This Quality Improvement study aims to assess baseline MASLD screening rates in a diabetes clinic and evaluate whether an EHR-based intervention increases disease recognition and early management.Methods: Medical charts from an […]

Introduction and Objective: QWINT-2 met its primary endpoint, with once weekly efsitora noninferior to once-daily degludec in reducing HbA1c at 52 weeks when added to existing noninsulin glucose-lowering agents in insulin-naïve adults with T2D. A Japan subgroup analysis is shown.Methods: QWINT-2 (NCT05362058) was a phase 3, randomized, parallel-design, open-label study. Participants were randomized 1:1 to […]

Introduction and Objective: To assess prevalence and factors for treatment failure with SGLT2i in US adults with T2D.Methods: This was a retrospective cohort study among US adults with T2D who initiated SGLT2i between January 1, 2016 and April 30, 2024, using the Komodo Healthcare MapTM database. Treatment failure occurred if they discontinued SGLT2i, added or […]

Introduction and Objective: EVs are membrane-bound nanoparticles that contribute to cell:cell communication. β cell EV PD-L1 protein is increased by interferon (IFN) exposure and is able to bind and inactivate CD8+ T cells, suggesting a role in the interplay between β cell destruction and survival in T1D. However, mechanisms underlying β cell PD-L1 incorporation into […]

Introduction and Objective: Calcium (Ca2+) is a key regulator of aerobic metabolism; yet, regulation of mitochondrial Ca2+ handling is understudied in pancreatic β-cells. The mitochondrial calcium uniporter (MCU) and mitochondrial sodium-calcium exchanger (NCLX) were identified as the major routes for Ca2+ influx and efflux across the inner mitochondrial membrane. Prior studies have shown that reduced […]

Introduction and Objective: Once-weekly (QW) insulins have emerged as a research focus due to their potential to enhance treatment acceptance and adherence by reducing injection frequency. This trial studied the efficacy and safety of a novel QW insulin analog GZR4 versus once-daily (QD) insulin degludec (IDeg) in basal insulin-treated subjects with T2D inadequately controlled by […]

Introduction and Objective: South Asian (SA) adult studies suggest insulin deficiency contributes to increased T2D risk. Our prior data found higher OGTT insulin in SA vs. White (W) and African American (AA) adolescents and young adults (AYA). Using mathematical modeling, we aim to investigate this finding by characterizing insulin sensitivity (Si), 1st pass hepatic extraction […]